Roivant Sciences CEO Matt Gline at #BIO24 (Brian Benton Photography)
September 10, 2024 06:30 AM EDTUpdated 11:15 AM
Deals

Roivant un­veils its next deal, hop­ing for TL1A-sized po­ten­tial from a shelved Bay­er lung dis­ease ther­a­py

Andrew Dunn

Senior Biopharma Correspondent

Near­ly a year af­ter agree­ing to a $7 bil­lion-plus sale for an in­flam­ma­to­ry bow­el dis­ease drug can­di­date, Roivant Sci­ences is pitch­ing big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times